LAUSR

pothetical oral pill among NDD-CKD patients. A lower chance of hospitalisation, a lower chance of requiring additional anemia therapy, and reducing the amount of “bad” cholesterol were also preferred by patients and were significant drivers of choice. Simplicity, convenience, and needle fear were included as reasons in the open text provided by patients, for increased patient value of the oral pill above SC and IV injections. Treatment attributes for frequency of administration, personnel, and location of medication collection and administration had lower importance to patients.As expected, patients’ preferences for all modes of administration decreased with increases in monthly out-ofpocket costs over the range $0-$75 AUD and $0-$150 CAD. Final data including similarities and differences between Australian and Canadian patients will be explored. Conclusions: The results of this DCE show that both Australian and Canadian NDD-CKD patients strongly preferred the hypothetical oral pill (holding all else constant). Our findings could be used as evidence to prioritise the most important characteristics of medications for anemia of CKD from the patients’ perspective. Conflict of Interest: This research was funded by AstraZeneca and conducted by CaPPRe. JS, EW, PB, SG, NR, DW, RK, AP are employed by AstraZeneca Limited and hold stock options. SF and BW are employed by CaPPRe. CaPPRe has consulted to Abbvie, Amgen, AstraZeneca, Celgene, GSK, Ipsen, Roche, Sanofi, and Shire, outside of the submitted work. DJ has received consultancy fees, research grants, speaker’s honoraria and travel sponsorships from Baxter Healthcare and Fresenius Medical Care, consultancy fees from AstraZeneca, Bayer and AWAK, speaker’s honoraria and travel sponsorships from ONO, and travel sponsorships from Amgen. He is a current recipient of an Australian National Health and Medical Research Council Practitioner Fellowship. KKT has received consultancy fees from Otsuka, AstraZeneca, Janssen and Baxter, and receives grant support from Otsuka and Astellas.